Patents by Inventor Carmen Cuevas
Carmen Cuevas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7507708Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.Type: GrantFiled: October 20, 2003Date of Patent: March 24, 2009Assignee: Pharma Mar, S.A.U.Inventors: Glynn Thomas Faircloth, Maria del Carmen Cuevas Marchante
-
Patent number: 7495000Abstract: Variolin derivatives of formula (5) are provided, wherein the substituent groups defined by X2, R1, R2, R3, R6, R7 and R12 are each independently selected from the group consisting of H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, NHSO2R?, CN, halogen, ?O, C(?O)H, C(?O)R?, CO2H, CO2R?, carboxyalkyl, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R? groups is independently selected from the group consisting of H, OH, SH, NO2, NH2, CN, halogen, ?O, C(?O)H, C(?O)CH3, CO2H, CO2CH3, C1-C12 alkyl, C2-C12 alkenyl, C2-C12alkynyl, aryl, aralkyl and heteroaromatic; wherein the pairs of groups R1 and R2, R2 and R3, R3 and R12, R12 and R6, or R6 and R7 may be joined into a carbocyclic or heterocyclic ring system.Type: GrantFiled: July 11, 2002Date of Patent: February 24, 2009Assignee: Pharma Mar, S.A.Inventors: Modesto Remuiñan, Juan Jose Gonzalez, Carlos Del Pozo, Carmen Cuevas, Simon Munt, Regan James Anderson, Andres Francesh, Jonathan Charles Morris, Ignacio Manzanares
-
Publication number: 20090030068Abstract: The invention relates to novel antitumor compounds of general formula as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.Type: ApplicationFiled: December 14, 2006Publication date: January 29, 2009Applicant: PHARMA MAR, S.A.Inventors: Ma Jesus Martin Lopez, Jose Fernando Reyes Benitez, Rogelio Fernandez Rodriguez, Andres Francesch Solloso, Maria del Carmen Cuevas Marchante, Laura Coello Molinero
-
Publication number: 20080318848Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.Type: ApplicationFiled: January 25, 2008Publication date: December 25, 2008Applicant: Pharma Mar S.A.U.Inventors: Glynn Faircloth, Maria del Carmen Cuevas Marchante
-
Patent number: 7446094Abstract: Compounds of general formula (I) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.Type: GrantFiled: June 23, 2004Date of Patent: November 4, 2008Assignee: Instituto Biomar S.A.Inventors: Paco Romero, Leyre Malet, Librada Maria Cañedo, Carmen Cuevas, José Fernando Reyes
-
Publication number: 20080269511Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substitType: ApplicationFiled: September 1, 2005Publication date: October 30, 2008Applicant: Pharma Mar S.A.U.Inventors: Carlos del Pozo Losada, Andres Francesch Solloso, Carmen Cuevas Marchante, Marta Perez Alvarez
-
Publication number: 20080227765Abstract: Compounds of general formula (1) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.Type: ApplicationFiled: June 23, 2004Publication date: September 18, 2008Inventors: Francisco Romero, Leyre Malet, Librada Canedo, Carmen Cuevas, Jose Reyes
-
Patent number: 7420051Abstract: Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.Type: GrantFiled: October 11, 2005Date of Patent: September 2, 2008Assignee: Pharma Mar, S.A.Inventors: Andrés Francesch, Carolina Fernández, José Luis Chicharro, Pilar Gallego, Maria Zarzuelo, Ignacio Manzanares, Marta Perez, Carmen Cuevas, María Jes{dot over (u)}s Martin, Simon Munt
-
Patent number: 7410969Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins.Type: GrantFiled: January 26, 2005Date of Patent: August 12, 2008Assignee: Pharma Mar, S.A.Inventors: Ignacio Manzanares, María Jesús Martin, Alberto Rodriguez, Simon Munt, Carmen Cuevas, Marta Perez
-
Patent number: 7396837Abstract: New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereofType: GrantFiled: August 13, 2003Date of Patent: July 8, 2008Assignee: Pharma Mar, S.A.U.Inventors: Christian Bailly, Andrés Francesch, Maria Cristina Mateo Urbano, José Antonio Jiménez Guerrero, Alfredo Pastor Del Castillo, Carmen Cuevas Marchante
-
Publication number: 20080103320Abstract: Compounds of the general formula (I) or pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(=O)H, C(=O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substitutType: ApplicationFiled: September 1, 2005Publication date: May 1, 2008Applicant: Pharma Mar S.A.U.Inventors: Carlos del Pozo Losada, Andres Francesch Solloso, Carmen Cuevas Marchante, Marta Perez Alvarez
-
Patent number: 7348310Abstract: The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.Type: GrantFiled: July 2, 2001Date of Patent: March 25, 2008Assignee: Pharma Mar, S.A.Inventors: Ignacio Rodriguez, Concepción Polanco, Felix Cuevas, Paloma Mendez, Carmen Cuevas, Pilar Gallego, Simon Munt, Ignacio Manzanares
-
Publication number: 20080051407Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.Type: ApplicationFiled: December 22, 2006Publication date: February 28, 2008Inventors: Ignacio Manzanares, Maria Martin, Alberto Rodriguez, Simon Munt, Carmen Cuevas, Marta Perez
-
Publication number: 20080045713Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an aryloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.Type: ApplicationFiled: July 9, 2007Publication date: February 21, 2008Applicant: Pharma Mar, S.A.Inventors: Carmen Cuevas, Marta Perez, Andres Francesch, Carolina Fernandez, Jose Chicharro, Pilar Gallego, Maria Zarzuelo, Fernando Calle, Ignacio Manzanares
-
Publication number: 20080009435Abstract: The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.Type: ApplicationFiled: April 20, 2007Publication date: January 10, 2008Inventors: Ignacio Rodriguez, Concepcion Polanco, Felix Cuevas, Paloma Mendez, Carmen Cuevas, Pilar Gallego, Simon Munt, Ignacio Manzanares
-
Patent number: 7247629Abstract: Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.Type: GrantFiled: May 15, 2001Date of Patent: July 24, 2007Assignee: Pharma Mar, S.A.Inventors: Ignacio Manzanares, María Jesús Martin, Alberto Rodriguez, Simon Munt, Carmen Cuevas, Marta Perez
-
Patent number: 7241892Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.Type: GrantFiled: May 15, 2000Date of Patent: July 10, 2007Assignee: Pharma Mar, S.A.Inventors: Carmen Cuevas, Marta Perez, Andres Francesch, Carolina Fernandez, Jose Luis Chicharro, Pilar Gallego, Maria Zarzuelo, Fernando de la Calle, Ignacio Manzanares
-
Publication number: 20070082878Abstract: Compounds of general formula (1) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.Type: ApplicationFiled: June 23, 2004Publication date: April 12, 2007Inventors: Francisco Romero, Leyre Malet, Librada Canedo, Carmen Cuevas, Jose Reyes
-
Patent number: 7138547Abstract: New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, CN, halogen, C(?O)H, C(?O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1–C18 alkyl, substituted or unsubstituted C2–C18 alkenyl, substituted or unsubstituted C2–C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form ?O; Y is NR1, OR1, PR1, SR1, or halogen, wherein the number of substituents R1 is selected to suit the valency and each R1 is independently selected of H, OH, C(?O)R?, P(?O)R?R?, substituted or unsubstituted C1–C18 alkyl, substituted or unsubstituted C2–C18 alkenyl, substituted or unsubstituted C2–C18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHC(O)R?, CN, halogen, C(?OType: GrantFiled: June 6, 2001Date of Patent: November 21, 2006Assignee: Pharma Mar, S.A.Inventors: Jose Luis Aceña, Javier Adrio, Carmen Cuevas, Pilar Gallego, Ignacio Manzanares, Simon Munt, Ignacio Rodriguez
-
Publication number: 20060235223Abstract: Variolin derivatives of formula (5) are provided, wherein the substituent groups defined by X2, R1, R2, R3, R6, R7 and R12 are each independently selected from the group consisting of H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, NHSO2R?, CN, halogen, ?O, C(?O)H, C(?O)R?, CO2H, CO2R?, carboxyalkyl, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R? groups is independently selected from the group consisting of H, OH, SH, N02, NH2, CN, halogen, ?O, C(?O)H, C(?O)CH3, CO2H, CO2CH3, C1-C12 alkyl, C2-C12 alkenyl, C2-C12alkynyl, aryl, aralkyl and heteroaromatic; wherein the pairs of groups R1 and R2, R2 and R3, R3 and R12, R12 and R6, or R6 and R7 may be joined into a carbocyclic or heterocyclic ring system.Type: ApplicationFiled: July 11, 2002Publication date: October 19, 2006Inventors: Modesto Remuiñan, Juan Gonzalez, Carlos Pozo, Carmen Cuevas, Simon Munt, Regan Anderson, Andres Francesh, Jonathan Morris, Ignacio Manzanares